Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine
- 1 September 2001
- journal article
- research article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 31 (9) , 1369-1377
- https://doi.org/10.1046/j.1365-2222.2001.01130.x
Abstract
Background Desloratadine is a non‐sedating, clinically effective, anti‐allergic therapy that has been shown to exhibit anti‐inflammatory properties that extend beyond its ability to antagonize histamine at H1‐receptor sites. This latter effect has been shown in vitro to be both IgE‐dependent and ‐independent. Objective In this study, we addressed the ability of desloratadine to inhibit the in vitro generation of interleukin (IL)‐4 and IL‐13 from human basophils while concurrently comparing its efficacy in preventing mediator release by these cells. Methods Basophil‐enriched suspensions were treated with various concentrations of desloratadine for 15 min before stimulating with either anti‐IgE antibody, calcium ionophore, IL‐3 or phorbol ester. Histamine (fluorimetry), LTC4 (RIA) and IL‐4 (ELISA) were all assayed using the same 4‐h culture supernatants. IL‐13 (ELISA) was measured in supernatants harvested after 20 h incubation. IL‐4 mRNA expression (dilutional RT‐PCR) was also examined. Results Desloratadine was found to be nearly six–seven times more potent in preventing the secretion of IL‐4 and IL‐13 induced by anti‐IgE than it was at inhibiting the release of histamine and LTC4. These cytokines were equally inhibited by desloratadine following activation with ionomycin despite the lack of an effect on the histamine induced with ionomycin. Desloratadine had a lesser effect regarding inhibition of the IL‐13 secreted in response to IL‐3 and PMA. There was no evidence that desloratadine mediated its inhibitory effects by causing decreased cell viability. Finally, IL‐4 mRNA accumulation was remarkably inhibited, by as much as 80%, following pretreatment with desloratadine. Conclusion While capable of inhibiting histamine and LTC4 release by human basophils, desloratadine is more effective at targeting the signals regulating IL‐4 and IL‐13 generation in these cells. This inhibitory effect on cytokine generation provides additional evidence that this antihistamine exerts anti‐inflammatory properties.Keywords
This publication has 22 references indexed in Scilit:
- 1123 Efficacy and safety of desloratadine in seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 2000
- 1122 Decongestant effects of desloratadine in patients with seasonal allegergin rhinitisJournal of Allergy and Clinical Immunology, 2000
- Cetirizine and hydrocortisone differentially regulate ICAM‐1 expression and chemokine release in cultured human keratinocytesClinical and Experimental Allergy, 1998
- Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cellsClinical and Experimental Allergy, 1997
- Loratadine and desethoxylcarbonyl‐loratadine inhibit the immunological release of mediators from human FcɛRI+cellsClinical and Experimental Allergy, 1997
- Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell linesExperimental Dermatology, 1995
- Cytokine generation by human basophilsJournal of Allergy and Clinical Immunology, 1994
- In vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3)Biochemical Pharmacology, 1994
- Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadineJournal of Allergy and Clinical Immunology, 1994
- Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or to calcium ionophoresNature, 1989